Table 2 Target volumes coverage for plans based on either lymphoscintigraphy (LS) volumes or international guidelines (IG) ones
Patient # | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Median | P-value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
CTVn-LS doses (%) | ||||||||||||
D95% | 100.2 | 103.7 | 100.0 | 99.2 | 100.9 | 102.9 | 99.8 | 98.9 | 99.8 | 99.5 | 99.91 | 0.232 |
D98% | 98.7 | 102.2 | 98.9 | 96.6 | 99.8 | 101.7 | 99.3 | 98.4 | 99.3 | 98.6 | 99.10 | 0.284 |
Dmean | 111.4 | 113.9 | 117.7 | 107.1 | 118.7 | 115.0 | 107.4 | 108.5 | 107.2 | 108.3 | 109.91 | 0.006 |
PTVn-LS doses (%) | ||||||||||||
D95% | 98.7 | 100.5 | 98.4 | 90.9 | 100.4 | 101.5 | 98.7 | 98.7 | 99.1 | 98.9 | 98.83 | 0.059 |
D98% | 97.5 | 97.5 | 88.5 | 80.0 | 99.1 | 100.2 | 96.9 | 98.2 | 98.4 | 98.2 | 97.84 | 0.185 |
Dmean | 111.0 | 111.8 | 114.2 | 102.9 | 117.1 | 114.1 | 106.1 | 108.5 | 106.3 | 106.8 | 109.73 | 0.006 |
CTVn-IG doses (%) | ||||||||||||
D95% | 98.2 | 99.5 | 100.0 | 97.8 | 100.9 | 101.2 | 100.5 | 99.6 | 99.3 | 100.2 | 99.82 | - |
D98% | 96.6 | 98.3 | 99.3 | 96.5 | 99.3 | 100.2 | 99.8 | 98.7 | 98.6 | 99.5 | 99.01 | - |
Dmean | 110.1 | 107.1 | 110.8 | 105.5 | 112.4 | 109.6 | 106.3 | 105.8 | 104.7 | 106.5 | 106.77 | - |
PTVn-IG doses (%) | ||||||||||||
D95% | 96.6 | 96.5 | 98.7 | 90.4 | 98.9 | 99.2 | 98.6 | 98.9 | 98.7 | 99.1 | 98.74 | - |
D98% | 88.1 | 94.1 | 95.1 | 82.0 | 96.6 | 97.3 | 95.5 | 98.0 | 98.0 | 97.3 | 96.04 | - |
Dmean | 109.2 | 105.2 | 108.6 | 101.8 | 111.0 | 108.4 | 105.2 | 105.4 | 104.3 | 104.7 | 105.32 | - |